GlassScriptPhysician profile
Ankur Shah
NPI 1851590343
$569,222.85
in general payments reported to CMS, 2019-2025
27 companies · $196K in 2025
The $196K reported for 2025 was more than what 99% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $22K · 2021: $13K · 2022: $40K · 2023: $148K · 2024: $134K · 2025: $196K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $283K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $70K · Travel and Lodging: $69K · Consulting Fee: $37K · Food and Beverage: $14K · Honoraria: $4,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $283,251.97 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $70,284.00 |
| Travel and Lodging | $69,413.57 |
| Consulting Fee | $36,651.00 |
| Food and Beverage | $13,616.08 |
| Honoraria | $4,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $264,117.79 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $218,266.91 | 2022-2025 | Syfovre, Syfovre |
| Astellas Pharma US INC | $27,807.62 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $15,964.72 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $11,147.57 | 2019-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $9,572.63 | 2024-2025 | Eylea Hd |
| Allergan, INC. | $8,737.55 | 2019-2021 | |
| Eyepoint US, INC. | $5,948.01 | 2019-2024 | |
| Ocular Therapeutix, INC. | $2,564.38 | 2025 | Dextenza |
| Abbvie INC. | $1,926.07 | 2022-2025 | Ozurdex |
| Novartis Pharmaceuticals Corporation | $1,281.03 | 2019-2020 | |
| Alcon Research LLC | $350.00 | 2023 | |
| Genentech, INC. | $289.00 | 2019-2022 | |
| Biogen, INC. | $278.99 | 2023-2024 | Byooviz |
| Harrow Eye, LLC | $165.02 | 2023-2025 | Iheezo, Triesence |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Amgen INC. | $146.07 | 2024-2025 | Tepezza, Pavblu |
| Astellas Pharma Global Development | $133.38 | 2025 | Izervay |
| Spark Therapeutics, INC. | $111.35 | 2019 | |
| Ani Pharmaceuticals, INC. | $61.92 | 2025 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $61.27 | 2023-2024 | Xipere, Visudyne, Retisert |
| Horizon Therapeutics Plc | $43.58 | 2022 | |
| Neurotech Pharmaceuticals, INC. | $29.72 | 2025 | |
| Alcon Vision LLC | $21.86 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.30 | 2019 | |
| Merck Sharp & Dohme LLC | $15.66 | 2024 | Verquvo |
| Dexcel Pharma Technologies LTD. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.